GlassScriptPhysician profile
Albert Huho
NPI 1295014249
$3,213.09
in general payments reported to CMS, 2019-2025
15 companies · $72.96 in 2025
The $72.96 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $12.38 · 2021: $451 · 2022: $1,028 · 2023: $1,400 · 2024: $78.89 · 2025: $72.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461 · Education: $91.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.01 |
| Education | $91.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $940.83 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $575.71 | 2022-2023 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $373.90 | 2022-2024 | Tremfya |
| Genzyme Corporation | $295.48 | 2022-2023 | |
| Lilly USA, LLC | $293.65 | 2022-2023 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $184.84 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $144.35 | 2023 | Ilumya |
| Janssen Scientific Affairs, LLC | $119.36 | 2022 | |
| Arcutis Biotherapeutics, INC. | $107.24 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $57.66 | 2022-2024 | Sotyktu |
| Incyte Corporation | $40.65 | 2023 | Opzelura |
| Blueprint Medicines Corporation | $24.82 | 2024 | Ayvakit |
| Amgen INC. | $22.24 | 2023 | Otezla |
| Pfizer INC. | $19.98 | 2023 | |
| Kyowa Kirin, INC. | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Huho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.